efgartigimod PH20 SC in stage B

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Drug Information

Target Indication

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Related Pipeline

Pemphigus Vulgaris

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Active Idiopathic Inflammatory Myopathy

Multifocal Motor Neuropathy (MMN)

Generalized Myasthenia Gravis